Literature DB >> 145319

Cardiac hypertrophy and antihypertensive therapy.

S Sen, R C Tarazi, F M Bumpus.   

Abstract

Biochemical (myocardial DNA, RNA, and hydroxyproline) and humoral (plasma [PRA] and kidney [KRA] renin activity) factors were determined in spontaneously hypertensive rats (SHR) and normotensive Wistar controls (NR) before and following treatment with minoxidil or propranolol. Minoxidil (150 mg.litre-1 drinking water) effectively controlled blood pressure (17.3 kPa vs 24.9 kPa [130 mmHg vs 187 mmHg], P less than 0.001) despite marked and sustained increases in both PRA and KRA ventricular weight which were not reduced and myocardial DNA, RNA, and hyperdroxyproline which were increased by minoxidil (P less than 0.01). In contrast propranolol did not reduce blood pressure in SHR but ventricular weight was reduced somewhat (3.1 +/- 0.4 mg.g-1 vs 3.4 +/- 0.09 mg.g-1, P less than 0.05); in both SHR and NR, KRA, and PRA were lowered by pranolol. Methyldopa which controlled blood pressure and lowered PRA led to a reversal of hypertrophy. Thus, although blood pressure control is obviously important for reversing cardiac hypertrophy, it may not be the sole factor for the development and reversal of cardiac hypertrophy.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 145319     DOI: 10.1093/cvr/11.5.427

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  30 in total

1.  Predicting and preventing hypertension and associated cardiovascular disease.

Authors:  S W Rabkin
Journal:  Can Fam Physician       Date:  1985-02       Impact factor: 3.275

Review 2.  Are different hemodynamic patterns of antihypertensive drugs clinically important?

Authors:  S Julius
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 3.  Hypertension.

Authors:  G W Ching; D G Beevers
Journal:  Postgrad Med J       Date:  1991-03       Impact factor: 2.401

4.  Pressure-independent enhancement of cardiac hypertrophy in natriuretic peptide receptor A-deficient mice.

Authors:  J W Knowles; G Esposito; L Mao; J R Hagaman; J E Fox; O Smithies; H A Rockman; N Maeda
Journal:  J Clin Invest       Date:  2001-04       Impact factor: 14.808

5.  Treatment of essential hypertension: changes in blood pressure, echocardiography and electrocardiography on three therapeutic regimes.

Authors:  G I Russell; J E Pohl; J Baldwin; R F Bing; A M Heagerty; H Thurston; J D Swales
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

6.  Control of blood pressure and reduction of echocardiographically assessed left ventricular mass with one-daily timolol.

Authors:  D B Rowlands; D R Glover; T J Stallard; W A Littler
Journal:  Br J Clin Pharmacol       Date:  1982-07       Impact factor: 4.335

7.  Effects of captopril on left ventricular structure and function in SHR with established hypertension.

Authors:  C A Canby; P J Palmer; K R Wall; R J Tomanek
Journal:  Basic Res Cardiol       Date:  1989 May-Jun       Impact factor: 17.165

8.  Left ventricular hypertrophy regression during antihypertensive treatment.

Authors:  H Eichstaedt; O Danne; R J Schroeder; D Kreuz
Journal:  Clin Investig       Date:  1992

Review 9.  Modulation of sympathetic outflow by centrally acting antihypertensive drugs.

Authors:  P A van Zwieten
Journal:  Cardiovasc Drugs Ther       Date:  1996-06       Impact factor: 3.727

10.  Enalapril reduces the enhanced 1,2-diacylglycerol content and RNA synthesis in spontaneously hypertensive rat hearts before established hypertension.

Authors:  K Okumura; J Kondo; M Yoshino; K Ishikawa; H Asano; H Hashimoto; T Ito
Journal:  Mol Cell Biochem       Date:  1992-05-13       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.